Manufacturing network

Miltenyi: reliable cell-therapy supply

From proprietary platforms and production of GMP reagents, including viral vectors, stimulation reagents, and optimized media, to global manufacturing, Miltenyi Biomedicine benefits from the Miltenyi Group’s complete end-to-end technology. This integration reduces bottlenecks, minimizes risk, and ensures consistency in supplying cell therapies worldwide.

CliniMACS Cell Factory® network

With over 25 years of expertise in cell therapy manufacturing, we leverage Miltenyi’s technology platforms directly within our clinical programs. Through Miltenyi Bioindustry, the CDMO arm of the Miltenyi Group, we profit from a global network of CliniMACS Cell Factory® facilities to provide reliable GMP production and process development.

What this means for clinical development:

Global reach: supply secured across multiple geographies for multi-center trials and supporting future commercialization.

Consistency: use of Miltenyi’s own GMP viral vectors, stimulation reagents, and media ensures harmonized standards and reproducible quality.

Scalability: the Cell Factory® network flexibly expands as clinical programs progress, supporting broader patient populations without disruption.

Find out more about our clinical programs

What makes Miltenyi's manufacturing approach unique?

Miltenyi Biomedicine benefits from full control of the cell therapy value chain, from proprietary platforms and GMP reagents to viral vectors and a global Cell Factory® network. This end-to-end integration helps minimize supply risk and ensure consistent quality across clinical sites.

How does the global network support trial delivery?

Through Miltenyi Bioindustry, our CDMO arm, we operate a worldwide Cell Factory® network to provide reliable supply, stable quality, and the flexibility to scale as clinical programs advance.